Neuronetics Stock Math Operators Price Series Summation
| STIM Stock | USD 1.36 0.06 4.62% |
| Symbols |
Operator |
This analysis covers sixty-one data points across the selected time horizon. Neuronetics Price Series Summation is a cross summation of Neuronetics price series and its benchmark/peer.
Neuronetics Technical Analysis Modules
Most technical analysis of Neuronetics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Neuronetics from various momentum indicators to cycle indicators. When you analyze Neuronetics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Neuronetics is scheduled to announce its earnings tomorrow.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Neuronetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 198 people. Liquidity and trading activity can influence how quickly new information is reflected in Neuronetics's price. Lower trading activity may introduce occasional variability in execution conditions. Neuronetics has a market cap of 88.69 M, ROE of -2.19%.
Methodology
Unless otherwise specified, financial data for Neuronetics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Neuronetics (USA Stocks:STIM) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Neuronetics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of DirectorsBecome your own money manager
Tracking Neuronetics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Adviser Favorites Invested few shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Dividend Beast Invested over 40 shares | |
 | Software Invested few shares | |
 | FinTech Invested over 20 shares | |
 | ESG Investing Invested few shares | |
 | Advertising Invested few shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Hedge Favorites Invested over 40 shares | |
 | Video Games Invested few shares | |
 | Baby Boomer Prospects Invested over 20 shares | |
More Resources for Neuronetics Stock Analysis
A structured review of Neuronetics often starts with core financial statements and trend context. Ratios and trend metrics help frame Neuronetics' operating context across reporting periods. Key reports that frame Neuronetics Stock are listed below:Neuronetics has a market cap of 88.69 M, operating margin of -19.63%, ROE of -2.19%. Use World Market Map to explore allocation context. This includes a position in Neuronetics inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. New to investing in Neuronetics Stock? Start with our How to Invest in Neuronetics Stock guide for a step-by-step overview.Neuronetics currently shows ROE of -2.19%, market cap of 88.69 Million. Neuronetics analysis should be paired with portfolio risk and diversification tools before adjusting allocations. A thorough Neuronetics review pairs this page with the quantitative and comparative resources listed below. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Earnings Share -0.83 | Revenue Per Share | Quarterly Revenue Growth 1.013 | Return On Assets | Return On Equity |
Understanding Neuronetics includes distinguishing between market value and book value, where book value reflects Neuronetics's accounting equity. Neuronetics' market capitalization is 88.69 M. The 3.25 P/B ratio shows Neuronetics carries a substantial premium over its balance-sheet equity. Enterprise value stands at 151.63 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Neuronetics' intrinsic value and market price are different measures derived from different inputs. For Neuronetics, key inputs include a P/B ratio of 3.25, a profit margin of -34.27%, ROE of -2.19%, and revenue of 74.89 M. The actual Neuronetics transaction price is determined by real-time order flow on the exchange.